- About
- Programs
- News
- Careers
- Contact
- Home
Products
Elara has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis.
Elara has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo.
Strategies to inhibit isolated enzymes or growth factors to prevent the formation of new blood vessels (angiogenesis) can successfully fight cancer. Several drugs interfering with angiogenesis are already on the market, e.g. bevacizumab, or have been approved recently (e.g. pazopanib, everolimus). However, Elara expects its approach to be superior to existing treatments as its HIF-inhibitors work upstream of established pathways and validated targets involved in tumor growth (e.g. VEGF).
Given the high potency and low toxicity of the drug candidates observed to date, Elara plans to develop its compounds as a monotherapy. However, combination with clinical standards of care or radiation therapy will be evaluated.
Pipeline
The company's lead candidate is in pre-clinical development and first-in-man studies are expected to start in 2011. The first indication will be Multiple Myeloma, a blood cancer with a high unmet medical need.
